Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
Latest Information Update: 14 Aug 2026
At a glance
- Drugs ACLX-002 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Proof of concept
- Sponsors Arcellx
Most Recent Events
- 11 Aug 2026 Planned End Date changed from 17 Nov 2025 to 1 Oct 2026.
- 11 Aug 2026 Planned primary completion date changed from 30 Sep 2025 to 1 Oct 2026.
- 11 Aug 2026 Status changed from recruiting to active, no longer recruiting.